Study of GS-1219 in Participants With HIV-1
Public ClinicalTrials.gov record NCT07115368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1; Substudy-04: GS-1219
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is part of a master study. The goal of master protocol (GSUS-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-04 is to learn more about study drug GS-1219, safety, pharmacokinetics (PK) (how GS-1219 is absorbed, modified, distributed, and removed from the body of the participants), and antiviral activity in Participants With HIV-1.
Study identification
- NCT ID
- NCT07115368
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 4 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 11, 2025 (Actual)
- Primary completion
- Sep 19, 2025 (Actual)
- Completion
- Oct 2, 2025 (Actual)
- Last update posted
- Oct 21, 2025
2025
United States locations
- U.S. sites
- 15
- U.S. states
- 6
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ruane Clinical Research Group | Los Angeles | California | 90036 | — |
| Mills Clinical Research | Los Angeles | California | 90069 | — |
| Quest Clinical Research | San Francisco | California | 94115 | — |
| Washington Health Institute | Washington D.C. | District of Columbia | 20017 | — |
| Midland Florida Clinical Research Center | DeLand | Florida | 32720 | — |
| Midway Immunology and Research Center | Ft. Pierce | Florida | 34982 | — |
| BLISS Health Inc | Orlando | Florida | 32803 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Triple O Research Institute | West Palm Beach | Florida | 33407 | — |
| Be Well Medical Center | Berkley | Michigan | 48072 | — |
| Central Texas Clinical Research | Austin | Texas | 78705 | — |
| Prism Health North Texas | Dallas | Texas | 75208 | — |
| North Texas Infectious Diseases Consultants | Dallas | Texas | 75246 | — |
| AXCES Research Group | El Paso | Texas | 79902 | — |
| AXCES Research Group | Salt Lake City | Utah | 84102 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07115368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07115368 live on ClinicalTrials.gov.